David Olmos (@Dolmos77)

Pinned

D

David Olmos@Dolmos77 · Feb 27, 2024

1/9 Glad to announce that the #CAPTURE study manuscript has been published today in @Annals_Oncology Would you like to learn more about it? Just follow this #tweetorial thread 👇 annalsofoncology.org/article/S0923-…

Dolmos77's tweet card. Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in homologous recombination...

4

40

83

21

17.0K

Pinned

David Olmos Retweeted

E

ESMO - Eur. Oncology@myESMO · Jun 26

Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations. Read the opinion by @Ecastromarcos in the #ESMODailyReporter 🔗 ow.ly/4kOC50WfVTQ #ProstateCancer #mHSPC #PersonalisedMedicine

2

7

29

1

2.0K

D

David Olmos@Dolmos77 · Jul 25

Datos de mutaciones BRCA y HRR en #prostatecancer hormonos sensible 🧑‍🤝‍🧑 mut HRR & BRCA similres en alto & bajo volumen 📢 El impacto de BRCA/HRR parece mayor el bajo volumen ⚠️Paciente con alt-BRCA tiene peeores resutaldos con dupletes (ACT+ARSI o ADT + Docetaxel)

EElena Castro@Ecastromarcos · Jul 25

Our last paper in @Annals_Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater impact in low volume😯. Doublets with ARPi or docetaxel result in comparable poor outcomes for BRCA pts annalsofoncology.org/article/S0923-…

0

14

29

3

3.0K

David Olmos Retweeted

R

Raffaele Di Giacomo, PhD@sciqst · Jul 25

This is an intriguing finding, Elena! It raises questions about whether treatment strategies should be more bespoke for mHSPC patients with BRCA mutations. Are there any hypotheses on why these mutations show a greater impact in low volume disease? Could personalized medicine…

0

1

2

0

159

David Olmos Retweeted

N

Noelia Tarazona@TarazonaNoelia · Jul 16

🔥Can we predict relapse in colon cancer before surgery❓Together with @HMar_research and @QuibimBiomarker, we built an AI-radiomics model that identifies high-risk patients from pre-op CT scans. 📌Published in @ESMO_Open 🔗sciencedirect.com/science/articl…

1

10

20

1

1.0K

David Olmos Retweeted

M

Misha Beltran@mishabeltran · Jul 1

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer @NatureComms rdcu.be/euijO Team science led by Kei Mizuno #BeltranLab @DanaFarber_GU @PCF_Science

2

21

59

2

5.0K

David Olmos Retweeted

p

pas_rescigno@PasRescigno · Jun 26

Another trial pointing at MMR defects as biomarker of ICI sensitivity in prostate cancer. Read ⬇️ @RMresearch_ @FenorLolin @AdamSharpMedOnc thank you to all the ICR team and Prof De Bono for this 💪🏻

1

7

19

4

1.0K

David Olmos Retweeted

Y

Yüksel Ürün@DrYukselUrun · Jun 24

p-value decoding guide: 0.0000000001 Nobel 🥇 0.049 🍾 0.050 😬 redo math 0.06 “Trending toward…” 0.08 p < 0.10? Why not? ≥0.1 Time for subgroup magic! @drkeithsiau

1

7

34

6

2.0K

D

David Olmos@Dolmos77 · Jun 24

+10 años liderando desde España la generación de conocimiento del papel de #BRCA1 #BRCA2 y otros genes de #HRR en #Cancer #próstata así como al desarrollo de #PARPi en esta enfermedad. Pero a día de hoy misión imposible Dx y tratar adecuadamente a estos pacientes en nuestro SNS

YYüksel Ürün@DrYukselUrun · Jun 24

🧬 BRCA mutations = worse prognosis in all mHSPC, regardless of disease volume or treatment. Risk stratification should include genomics. Congratulations David and all team. 👏👏👏 @Dolmos77 @Ecastromarcos @cdanicas @Annals_Oncology @tompowles1 @APCCC_Lugano @OncoAlert…

0

10

52

10

4.0K

David Olmos Retweeted

E

European Urology@EUplatinum · Jun 24

📢 NEW in European Urology by Johann S. de Bono et al. 🧬 Final OS results from the phase 3 IPATential150 trial: ❌ No OS benefit from adding ipatasertib to abiraterone in mCRPC with PTEN loss (by IHC) 🔍 Exploratory NGS suggests AKT pathway alterations (PIK3CA/AKT1/PTEN, RTK)…

1

8

2

1.0K

David Olmos Retweeted

Y

Yüksel Ürün@DrYukselUrun · Jun 24

🧬 BRCA mutations = worse prognosis in all mHSPC, regardless of disease volume or treatment. Risk stratification should include genomics. Congratulations David and all team. 👏👏👏 @Dolmos77 @Ecastromarcos @cdanicas @Annals_Oncology @tompowles1 @APCCC_Lugano @OncoAlert…

1

31

103

30

10.0K

David Olmos Retweeted

B

Bernardo Herrera Imbroda@BerUrologia · Jun 22

Un placer compartir junto a @Dolmos77⁩ este reconocimiento de ⁦@GacetaMedicaCom⁩ sobre nuestro proyecto #capture ⁦@H12Octubre⁩ ⁦@HUVV_SAS⁩ ⁦@_ibima⁩ @saludand recordando la importancia del diagnostico molecular en ca de prostata gacetamedica.com/investigacion/…

0

3

10

0

329

David Olmos Retweeted

A

Ainhoa Madariaga@AinhoaMada · Jun 22

Back from an inspiring #ESMOGynae25 🇦🇹 Fantastic opportunity to learn from 🔝 faculty & Network Honoured to receive the #BestPoster award @H12Octubre & share an #ADC session with Philip Harter & Christian Marth

1

2

49

1

2.0K

David Olmos Retweeted

O

Oncobites.tv@OncobitesTv · Jun 18

🧬 ¿BRCA en próstata? El volumen ya no es lo más importante. El estudio CAPTURE, liderado por @Dolmos77 y @ECastromarcos desde el Hospital 12 de Octubre, demuestra que las mutaciones en BRCA1/2 empeoran el pronóstico en cáncer de próstata, independientemente del volumen…

0

2

8

1

393

D

David Olmos@Dolmos77 · Jun 16

Excited to see our work published in @CCR_AACR ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team @RyonGraf @umangtalking @neerajaiims @urotoday @OncoAlert

NNeeraj Agarwal, MD, FASCO@neerajaiims · Jun 16

Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i @OncoAlert @urotoday

9

23

72

4

10.0K

David Olmos Retweeted

p

pas_rescigno@PasRescigno · Jun 17

Happy to talk about BRCA2 mut in prostate cancer at the British Association of Urological Surgeons #BAUS25 In Manchester! Great vibes 💪🏻

0

1

11

0

339

D

David Olmos@Dolmos77 · Jun 16

@Dolmos77 @Dav_Lorente

EEuropean Urology@EUplatinum · Jun 16

🧬 In prostate cancer, not all #HRR alterations are equal. In this @EUplatinum editorial, @Ecastromarcos, Olmos & Lorente dissect the nuanced response to #PARP inhibitors—highlighting gene-specific efficacy, regulatory discord between FDA & EMA, and future challenges. 📖 Read:…

0

4

14

0

446

David Olmos Retweeted

E

European Urology@EUplatinum · Jun 16

🧬 In prostate cancer, not all #HRR alterations are equal. In this @EUplatinum editorial, @Ecastromarcos, Olmos & Lorente dissect the nuanced response to #PARP inhibitors—highlighting gene-specific efficacy, regulatory discord between FDA & EMA, and future challenges. 📖 Read:…

0

14

48

17

5.0K

D

David Olmos@Dolmos77 · Jun 12

👏👏👏

EElena Castro@Ecastromarcos · Jun 12

Mary-Claire King to receive the Princesa de Asturias award in Spain for her work in genetics. She is known for identifying BRCA1 and BRCA2 and describing the Hereditary Breast and Ovarian Cancer Syndrome. This just one of her multiple contributions to science. @myESMO @AECC

0

3

0

106

David Olmos Retweeted

E

Elena Castro@Ecastromarcos · Jun 12

Mary-Claire King to receive the Princesa de Asturias award in Spain for her work in genetics. She is known for identifying BRCA1 and BRCA2 and describing the Hereditary Breast and Ovarian Cancer Syndrome. This just one of her multiple contributions to science. @myESMO @AECC

3

12

44

0

2.0K